EVOQ Nano, Inc.
EVŌQ Nano is a nanoscience company dedicated to engineering innovative nanoparticles for healthcare, materials, and textile industries. Their mission is to combat antimicrobial resistance (AMR) by developing advanced nanotechnologies, including a patented laser nanofabrication process that produces stable, sub-10 nm nanoparticles. Their flagship product EVQ-218 is a non-ionic silver nanoparticle with demonstrated efficacy against drug-resistant bacteria and fungi, with potential applications in medical devices, therapeutics, and antimicrobial solutions. The company is actively advancing its research, development, and clinical trials, including a significant milestone with FDA approval processes for inhaled therapies targeting pulmonary infections in cystic fibrosis patients. EVŌQ Nano is backed by $20 million in seed funding, with strategic partnerships and a team of experts in nanoscience and biotech.
Industries
Nr. of Employees
small (1-50)
EVOQ Nano, Inc.
Patents
Use of nanoparticles for treating respiratory infections associated with cystic fibrosis
US-12115250-B2
View DetailsNanoparticle compositions and methods for treating or preventing tissue infections and diseases
US-10953043-B2
View DetailsNanoparticle treated fabrics, fibers, filaments, and yarns and related methods
US-10190253-B2
View DetailsNanoparticle compositions and methods for treating or preventing tissue infections and diseases
US-9839652-B2
View Details
Use of nanoparticles for treating respiratory infections associated with cystic fibrosis
US-12115250-B2
View DetailsNanoparticle compositions and methods for treating or preventing tissue infections and diseases
US-10953043-B2
View DetailsNanoparticle treated fabrics, fibers, filaments, and yarns and related methods
US-10190253-B2
View DetailsNanoparticle compositions and methods for treating or preventing tissue infections and diseases
US-9839652-B2
View DetailsProducts
Surfactant-free non-ionic metal nanoparticle platform for antimicrobial applications
Uniform, sub-10 nm, surfactant-free metal nanoparticle technology designed for antimicrobial use across therapeutics, medical devices, and surface/textile treatments; characterized in peer-reviewed literature and reported to national-standard-comparable metrics.
Surfactant-free non-ionic metal nanoparticle platform for antimicrobial applications
Uniform, sub-10 nm, surfactant-free metal nanoparticle technology designed for antimicrobial use across therapeutics, medical devices, and surface/textile treatments; characterized in peer-reviewed literature and reported to national-standard-comparable metrics.
Services
Design and execution of in vitro and in vivo efficacy and safety studies, IND-enabling activities, and regulatory engagement to support transition to Phase I clinical trials for inhaled nanoparticle formulations.
Co-development, licensing, and testing partnerships to embed nanoparticles into polymers and validate antimicrobial performance on device components such as catheters and fittings.
Commercial contracts and licensing for application of EPA-registered antimicrobial chemistries to textiles, workspaces, and consumer products.
Design and execution of in vitro and in vivo efficacy and safety studies, IND-enabling activities, and regulatory engagement to support transition to Phase I clinical trials for inhaled nanoparticle formulations.
Co-development, licensing, and testing partnerships to embed nanoparticles into polymers and validate antimicrobial performance on device components such as catheters and fittings.
Commercial contracts and licensing for application of EPA-registered antimicrobial chemistries to textiles, workspaces, and consumer products.
Expertise Areas
- Laser-based nanofabrication for scale-up
- Nanoparticle materials engineering and surface-state control
- Inhaled nanotherapeutics for pulmonary infections (preclinical)
- Mechanism-driven antimicrobial development (intracellular metabolic disruption)
Key Technologies
- Laser ablation nanoparticle synthesis
- Production of uniform sub-10 nm nanoparticles
- Surfactant-free non-ionic metal nanoparticle formulations
- Nanoparticle embedding in polymer matrices
News & Updates
EVQ-218, a non-ionic silver nanoparticle developed by EVŌQ Nano, has shown efficacy against the WHO’s top six antibiotic-resistant bacterial strains, offering a promising solution to combat superbugs without triggering antimicrobial resistance.
EVQ-218 has successfully completed a pre-investigational new drug (pre-IND) meeting with the FDA, advancing towards Phase I clinical trials for treating pulmonary bacterial infections in cystic fibrosis patients.
EVQ-218 employs a novel mechanism that kills bacteria from the inside by sequestering sulfur, preventing the activation of resistance pathways, and showing efficacy against drug-resistant strains.
Created the first and only non-ionic silver nanoparticle with demonstrated efficacy against resistant bacteria and fungi, with a patented laser nanofabrication process.
EVQ-218, a non-ionic silver nanoparticle developed by EVŌQ Nano, has shown efficacy against the WHO’s top six antibiotic-resistant bacterial strains, offering a promising solution to combat superbugs without triggering antimicrobial resistance.
EVQ-218 has successfully completed a pre-investigational new drug (pre-IND) meeting with the FDA, advancing towards Phase I clinical trials for treating pulmonary bacterial infections in cystic fibrosis patients.
EVQ-218 employs a novel mechanism that kills bacteria from the inside by sequestering sulfur, preventing the activation of resistance pathways, and showing efficacy against drug-resistant strains.
Created the first and only non-ionic silver nanoparticle with demonstrated efficacy against resistant bacteria and fungi, with a patented laser nanofabrication process.